Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 3/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2901152 | 0.98 | NAAA (0.40) | NAAAEPHX1HTTCYP2C19CYP19A1 | |
| SCHEMBL4312944 | 0.95 | NAAA (0.38) | NAAAEPHX1HTTCYP2C19CYP19A1 | |
| SCHEMBL4307907 | 0.93 | NAAA (0.39) | NAAAEPHX1HTTCYP2C19CYP19A1 | |
| SCHEMBL4307836 | 0.93 | NAAA (0.40) | NAAAEPHX1HTTCYP2C19CYP19A1 | |
| SCHEMBL9034880 | 0.92 | NAAA (0.30) | NAAA | |
| SCHEMBL5245472 | 0.89 | EPHX1 (0.39) | NAAAEPHX1HTTCYP2C19CYP19A1 | |
| SCHEMBL8579936 | 0.87 | EPHX1 (0.42) | NAAAEPHX1HTTCYP2C19CYP19A1 | |
| SCHEMBL1559459 | 0.87 | EPHX1 (0.42) | NAAAEPHX1HTTCYP2C19CYP19A1 | |
| SCHEMBL9035280 | 0.85 | EPHX1 (0.35) | NAAAEPHX1HTTCYP2C19CYP19A1 | |
| SCHEMBL450933 | 0.81 | NAAA (0.54) | NAAAEPHX1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4138923-A1 | DRUG ANTIBODY CONJUGATES | Pharma Mar, S.A. (ES) | 2023-03-01 | — | — | EP | disclosed |
| WO-2021214126-A1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR, S.A. (ES) | 2021-10-28 | — | — | WO | disclosed |
| WO-2009136965-A1 | COMPOSITIONS AND METHODS COMPRISING CAPURAMYCIN ANALOGUES | SEQUELLA, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| EP-1919290-A2 | METHODS AND PRODUCTS FOR TREATMENT OF DISEASES | DMI Biosciences, Inc. (US) | 2008-05-14 | — | — | EP | disclosed |
| EP-1898951-A1 | PHARMACEUTICAL PREPARATION CONTAINING AN ANGIOTENSIN II RECEPTOR ANTAGONIST AND A CALCIUM CHANNEL BLOCKER | Daiichi Sankyo Company, Limited (JP) | 2008-03-19 | — | — | EP | disclosed |
| WO-2007009087-A2 | METHODS AND PRODUCTS FOR TREATMENT OF DISEASES | DMI BIOSCIENCES, INC. (US) | 2007-01-18 | — | — | WO | disclosed |
| WO-2007001066-A1 | PHARMACEUTICAL PREPARATION CONTAINING AN ANGIOTENSIN II RECEPTOR ANTAGONIST AND A CALCIUM CHANNEL BLOCKER | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007001067-A2 | SOLID DOSAGE FORM COMPRISING AN ANGIOTENSIN II RECEPTOR ANTAGONIST AND A CALCIUM CHANNEL BLOCKER | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007001065-A2 | METHOD FOR THE PREPARATION OF A WET GRANULATED DRUG PRODUCT | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2007-01-04 | — | — | WO | disclosed |
| US-6242611-B1 | SUCH AS 4-(4,4-DIMETHYL-2,5-DIOXO-3-(4-NITROOXYBUTYL) -1-IMIDAZOLIDINYL)-2-(TRIFLUOROMETHYL)BENZONITRILE USED AS ANTIANDROGENIC COMPOUNDS | HOECHST MARION ROUSSEL (FR) | 2001-06-05 | — | — | US | disclosed |
| EP-0869946-A1 | PHENYLIMIDAZOLIDINES AND USE THEREOF AS AN ANTIANDROGENIC AGENT | HOECHST MARION ROUSSEL (FR) | 1998-10-14 | — | — | EP | disclosed |
| EP-0763053-A4 | STEROID DERIVATIVES FOR TREATMENT OF 5 ALPHA REDUCTASE | SMITHKLINE BEECHAM CORP (US) | 1998-09-09 | — | — | EP | disclosed |
| WO-1997023464-A1 | PHENYLIMIDAZOLIDINES AND USE THEREOF AS AN ANTIANDROGENIC AGENT | HOECHST MARION ROUSSEL (FR) | 1997-07-03 | — | — | WO | disclosed |
| EP-0763053-A1 | STEROID DERIVATIVES FOR TREATMENT OF 5 ALPHA REDUCTASE | SMITHKLINE BEECHAM CORPORATION (US) | 1997-03-19 | — | — | EP | disclosed |
| EP-0721454-A1 | NEW PYRAZOLE DERIVATIVES AS ANGIOTENSIN II ANTAGONIST | J. URIACH & CIA. S.A. (ES) | 1996-07-17 | — | — | EP | disclosed |
| WO-1995033761-A1 | STEROID DERIVATIVES FOR TREATMENT OF 5 ALPHA REDUCTASE | SMITHKLINE BEECHAM CORPORATION (US) | 1995-12-14 | — | — | WO | disclosed |